Etoposide-platinum + atezolizumab (extensive SCLC, 1L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-CARBOPLATIN` `DRUG-ETOPOSIDE` `DRUG-ATEZOLIZUMAB`

ID	`REG-EP-ATEZO-SCLC`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-SCLC-2021` `SRC-NCCN-SCLC-2025`

Notes

IMpower133: median OS 12.3 (EP+atezo) vs 10.3 months (EP alone) in extensive SCLC 1L. Cisplatin substitute possible (less common in modern practice).

Used By

Regimen

REG-CE-SCLC - Carboplatin + etoposide (SCLC, 1L)